Boehringer Ingelheim Cares Product Donations Program
Boehringer Ingelheim Cares Product Donations Program
Search
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
Making Toys for Shelter Animals | Boehringer Ingelheim US
Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.
Ordering your medicine online? Find a safe pharmacy first.
Learn what to look for when buying medication and how to verify your pharmacy.
Ivermectin in Animal Health products and COVID-19
Ivermectin in Animal Health products and COVID-19
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
Jardiance® (empagliflozin) analysis reinforces established safety profile
Jardiance® (empagliflozin) analysis reinforces established safety profile
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.
Yamagata
With its location in the Yamagata prefecture (Higashine), this site focuses on the production & packaging of human pharmaceuticals for the Japanese market.
Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US
The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.
Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.
Talking drug discovery with our U.S. research site head, Carine Boustany
Learn about the challenges and victories of developing new medicine for conditions, like generalized pustular psoriasis (GPP) flares in adults.
Retinal Health
Retinal Health
Championing for people with all abilities
Every diverse background brings unique perspectives to our company.
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
Pioneers who inspire: Women in livestock
Pioneers who inspire: Women in livestock
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Experience our culture during your interview process
Discover if our company is the right fit for you.
Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Advocating for More Patient-Centered Mental Health Care
Advocating for More Patient-Centered Mental Health Care
BI Cares Signature Program: Empowering Patients to Make Healthy Lifestyle Changes
Signature Program
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment